Published in Int J Parasitol on February 01, 2001
Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii. Proc Natl Acad Sci U S A (2006) 1.93
Toxoplasma gondii scavenges host-derived lipoic acid despite its de novo synthesis in the apicoplast. EMBO J (2006) 1.42
Maternal inheritance and stage-specific variation of the apicoplast in Toxoplasma gondii during development in the intermediate and definitive host. Eukaryot Cell (2005) 1.37
Delivery of antimicrobials into parasites. Proc Natl Acad Sci U S A (2003) 1.31
Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches. FASEB J (2011) 1.31
A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum. Antimicrob Agents Chemother (2003) 1.26
Make it or take it: fatty acid metabolism of apicomplexan parasites. Eukaryot Cell (2007) 1.20
Current advances in detection and treatment of babesiosis. Curr Med Chem (2012) 1.11
Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis (2008) 1.10
Apicoplast and endoplasmic reticulum cooperate in fatty acid biosynthesis in apicomplexan parasite Toxoplasma gondii. J Biol Chem (2011) 1.09
Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrob Agents Chemother (2012) 1.07
The apicomplexan plastid and its evolution. Cell Mol Life Sci (2011) 1.03
Toxoplasma gondii acyl-lipid metabolism: de novo synthesis from apicoplast-generated fatty acids versus scavenging of host cell precursors. Biochem J (2006) 1.02
The crystal structure of PfFabZ, the unique beta-hydroxyacyl-ACP dehydratase involved in fatty acid biosynthesis of Plasmodium falciparum. Protein Sci (2005) 1.00
Lipidomic analysis of Toxoplasma gondii reveals unusual polar lipids. Biochemistry (2007) 1.00
Slow-tight-binding inhibition of enoyl-acyl carrier protein reductase from Plasmodium falciparum by triclosan. Biochem J (2004) 0.98
Targeting the Lipid Metabolic Pathways for the Treatment of Malaria. Drug Dev Res (2010) 0.98
Enzymes of type II fatty acid synthesis and apicoplast differentiation and division in Eimeria tenella. Int J Parasitol (2006) 0.98
Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents. Acta Crystallogr D Biol Crystallogr (2007) 0.98
Parasite plastids: maintenance and functions. Philos Trans R Soc Lond B Biol Sci (2003) 0.98
Lipid synthesis in protozoan parasites: a comparison between kinetoplastids and apicomplexans. Prog Lipid Res (2013) 0.96
Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J Med Chem (2010) 0.95
Multiple triclosan targets in Trypanosoma brucei. Eukaryot Cell (2004) 0.95
Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase. ChemMedChem (2008) 0.94
Triclosan: current status, occurrence, environmental risks and bioaccumulation potential. Int J Environ Res Public Health (2015) 0.93
Absorption, pharmacokinetics, and safety of triclosan after dermal administration. Antimicrob Agents Chemother (2009) 0.92
Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase. Bioorg Med Chem Lett (2008) 0.90
Metabolic pathway analysis in trypanosomes and malaria parasites. Philos Trans R Soc Lond B Biol Sci (2002) 0.90
Type I and type II fatty acid biosynthesis in Eimeria tenella: enoyl reductase activity and structure. Parasitology (2007) 0.88
Fatty acid synthesis and pyruvate metabolism pathways remain active in dihydroartemisinin-induced dormant ring stages of Plasmodium falciparum. Antimicrob Agents Chemother (2014) 0.88
Novel type II fatty acid biosynthesis (FAS II) inhibitors as multistage antimalarial agents. ChemMedChem (2013) 0.87
Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase. Bioorg Med Chem Lett (2013) 0.84
Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents. J Med Chem (2009) 0.84
Expression, purification and preliminary crystallographic analysis of the Toxoplasma gondii enoyl reductase. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 0.83
Dual-resolution molecular dynamics simulation of antimicrobials in biomembranes. J R Soc Interface (2010) 0.83
Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother (2013) 0.82
Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity. Antimicrob Agents Chemother (2015) 0.79
Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii. ChemMedChem (2013) 0.77
Celastrol inhibits Plasmodium falciparum enoyl-acyl carrier protein reductase. Bioorg Med Chem (2014) 0.77
Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay. Biochemistry (2013) 0.77
The benzimidazole based drugs show good activity against T. gondii but poor activity against its proposed enoyl reductase enzyme target. Bioorg Med Chem Lett (2013) 0.76
Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression. BMC Genomics (2015) 0.76
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides. Bioorg Med Chem Lett (2013) 0.76
In silico screening for Plasmodium falciparum enoyl-ACP reductase inhibitors. J Comput Aided Mol Des (2014) 0.75
Multivariate PLS Modeling of Apicomplexan FabD-Ligand Interaction Space for Mapping Target-Specific Chemical Space and Pharmacophore Fingerprints. PLoS One (2015) 0.75
Rational design and synthesis of novel diphenyl ether derivatives as antitubercular agents. Drug Des Devel Ther (2016) 0.75
Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Devel Ther (2017) 0.75
Anti-malarial Drug Design by Targeting Apicoplasts: New Perspectives. J Pharmacopuncture (2016) 0.75
Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications. Parasitol Res (2017) 0.75
Detecting protein function and protein-protein interactions from genome sequences. Science (1999) 18.69
A molecular evolutionary framework for the phylum Nematoda. Nature (1998) 10.64
DIP: the database of interacting proteins. Nucleic Acids Res (2000) 10.06
Escherichia coli recA gene product inactivates phage lambda repressor. Proc Natl Acad Sci U S A (1978) 5.42
The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg (1996) 5.35
Proteolytic cleavage of bacteriophage lambda repressor in induction. Proc Natl Acad Sci U S A (1975) 5.16
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet (1996) 4.90
Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature (1990) 4.61
Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science (1987) 4.36
Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci U S A (1990) 3.98
Evidence for the shikimate pathway in apicomplexan parasites. Nature (1998) 3.60
Inactivation and proteolytic cleavage of phage lambda repressor in vitro in an ATP-dependent reaction. Proc Natl Acad Sci U S A (1977) 3.47
Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg (1996) 3.36
Cardiac effects of antimalarial treatment with halofantrine. Lancet (1993) 3.32
Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet (2001) 3.30
Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science (1987) 3.25
Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol Biochem Parasitol (1993) 3.16
Homology between CAP and Fnr, a regulator of anaerobic respiration in Escherichia coli. J Mol Biol (1983) 3.08
Ferritin: design and formation of an iron-storage molecule. Philos Trans R Soc Lond B Biol Sci (1984) 2.94
Sequence, structure and activity of phosphoglycerate kinase: a possible hinge-bending enzyme. Nature (1979) 2.88
Activity of the Escherichia coli recA-gene product. Cold Spring Harb Symp Quant Biol (1979) 2.75
Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science (1991) 2.64
Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis (1996) 2.59
Antitermination by bacteriophage lambda Q protein. Cold Spring Harb Symp Quant Biol (1998) 2.57
Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Trans R Soc Trop Med Hyg (1998) 2.54
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8 A resolution. J Mol Biol (1989) 2.53
Comparison of the three-dimensional structures of recombinant human H and horse L ferritins at high resolution. J Mol Biol (1997) 2.49
Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc Natl Acad Sci U S A (2001) 2.41
New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother (1984) 2.32
Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. Exp Parasitol (1988) 2.29
Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br J Clin Pharmacol (1996) 2.19
Molecular basis of triclosan activity. Nature (1999) 2.18
CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice. Clin Exp Immunol (1991) 2.10
In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob Agents Chemother (1985) 2.07
A mechanism of drug action revealed by structural studies of enoyl reductase. Science (1996) 2.03
Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother (2001) 2.01
Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science (1988) 2.00
Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: evidence for quinine resistance. Am J Trop Med Hyg (1998) 1.92
A graph-theoretic approach to the identification of three-dimensional patterns of amino acid side-chains in protein structures. J Mol Biol (1994) 1.88
Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol (2003) 1.87
PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg (1993) 1.84
Genetic regulation of early survival and cyst number after peroral Toxoplasma gondii infection of A x B/B x A recombinant inbred and B10 congenic mice. J Immunol (1989) 1.82
Use of techniques derived from graph theory to compare secondary structure motifs in proteins. J Mol Biol (1990) 1.82
Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg (2006) 1.75
Conformational flexibility in glutamate dehydrogenase. Role of water in substrate recognition and catalysis. J Mol Biol (1993) 1.67
Identification of the gene for the yeast ribonucleotide reductase small subunit and its inducibility by methyl methanesulfonate. Mol Cell Biol (1987) 1.63
Qualitative and semiquantitative polymerase chain reaction to predict Plasmodium falciparum treatment failure. J Infect Dis (1994) 1.61
On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11(-)/-) mutant mice. J Exp Med (1997) 1.59
Two mutations that alter the regulatory activity of E. coli recA protein. Nature (1981) 1.58
Protein thermostability above 100 degreesC: a key role for ionic interactions. Proc Natl Acad Sci U S A (1998) 1.56
Crystal structure of DNA recombination protein RuvA and a model for its binding to the Holliday junction. Science (1996) 1.54
Crystal structure of the Lrp-like transcriptional regulator from the archaeon Pyrococcus furiosus. EMBO J (2001) 1.53
In vitro sensitivity of Plasmodium falciparum to artesunate in Thailand. Bull World Health Organ (1999) 1.52
Molecular analysis of Plasmodium falciparum recrudescent malaria infections in children treated with chloroquine in Nigeria. Am J Trop Med Hyg (2004) 1.51
Subunit assembly and active site location in the structure of glutamate dehydrogenase. Proteins (1992) 1.50
Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria. Am J Trop Med Hyg (2001) 1.49
Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. Antimicrob Agents Chemother (1990) 1.49
Glycerol dehydrogenase. structure, specificity, and mechanism of a family III polyol dehydrogenase. Structure (2001) 1.48
Reduced in-vitro susceptibility to mefloquine in West African isolates of Plasmodium falciparum. Lancet (1987) 1.46
The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. Ann Trop Med Parasitol (1993) 1.45
Vacuolar uptake of host components, and a role for cholesterol and sphingomyelin in malarial infection. EMBO J (2000) 1.45
Analysis of Plasmodium falciparum PfEMP-1/var genes suggests that recombination rearranges constrained sequences. Mol Biochem Parasitol (1999) 1.43
Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure. Exp Parasitol (1989) 1.42
Lactate dehydrogenase and the diagnosis of malaria. Parasitol Today (1998) 1.41
Bisquinolines. 1. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria. J Med Chem (1992) 1.40
Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro. Antimicrob Agents Chemother (1989) 1.40
Method to increase the sensitivity of poliovirus isolation. Lancet (1992) 1.39
HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol (1999) 1.39
Identification of tertiary structure resemblance in proteins using a maximal common subgraph isomorphism algorithm. J Mol Biol (1993) 1.38
Structural consequences of sequence patterns in the fingerprint region of the nucleotide binding fold. Implications for nucleotide specificity. J Mol Biol (1992) 1.38
Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop (2005) 1.37
Crystal structure of E.coli RuvA with bound DNA Holliday junction at 6 A resolution. Nat Struct Biol (1998) 1.36
Structural relationship between glutathione reductase and lipoamide dehydrogenase. J Mol Biol (1984) 1.36
Immune response of mice to ingested Toxoplasma gondii: a model of toxoplasma infection acquired by ingestion. J Infect Dis (1984) 1.35
Cooperative tandem binding of met repressor of Escherichia coli. Nature (1989) 1.33
Delivery of antimicrobials into parasites. Proc Natl Acad Sci U S A (2003) 1.31
Point mutations in the pfcrt and pfmdr-1 genes of Plasmodium falciparum and clinical response to chloroquine, among malaria patients from Nigeria. Ann Trop Med Parasitol (2003) 1.29
Plasmodium falciparum: evaluation of lactate dehydrogenase in monitoring therapeutic responses to standard antimalarial drugs in Nigeria. Exp Parasitol (1997) 1.27
8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. Antimicrob Agents Chemother (1991) 1.27
A comparison of the in vitro activities of amodiaquine and desethylamodiaquine against isolates of Plasmodium falciparum. Am J Trop Med Hyg (1989) 1.27
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis (1999) 1.26
Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am J Trop Med Hyg (1996) 1.26
Morphologic effects of artemisinin in Plasmodium falciparum. Am J Trop Med Hyg (1993) 1.25
The Met repressor-operator complex: DNA recognition by beta-strands. Ann N Y Acad Sci (1994) 1.25
Analysis of the structure, substrate specificity, and mechanism of squash glycerol-3-phosphate (1)-acyltransferase. Structure (2001) 1.23